|Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550|
|A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550|
|The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis. Subjects are only eligible for this study after they have completed all participation in other studies of CP-690,550.|
|At their last visit of a qualifying study, eligible subjects will be given the opportunity to participate in this study.|
|Observational Model: Cohort|
Time Perspective: Prospective
|Subjects who have received at least one dose of study drug and ceased participation in any Phase 2B or 3 randomized, controlled or open-label (qualifying) study of CP-690,550 for the treatment of RA, but are no longer receiving CP-690,550.|
Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
All enrolled subjects
Intervention: Drug: CP-690,550
|February 2012 (Final data collection date for primary outcome measure)|
- Subjects who have completed all participation in any other Phase 2B or Phase 3 studies of CP-690,550 for rheumatoid arthritis.
- Any subject who refuses consent.
|Sexes Eligible for Study:||All|
|18 Years and older (Adult, Older Adult)|
|Contact information is only displayed when the study is recruiting subjects|
|Argentina, Brazil, Bulgaria, Canada, Chile, Czech Republic, Dominican Republic, Finland, Greece, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Poland, Puerto Rico, Slovakia, Spain, Ukraine, United States|
|Australia, Austria, Belgium, Costa Rica, Romania, Sweden|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|